Form 8-K ABBOTT LABORATORIES For: Dec 22

�

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

�

�

FORM�8-K

�

CURRENT REPORT

Pursuant to Section�13 or 15(d)�of the

Securities Exchange Act of 1934

�

Date of Report (Date of earliest event reported): �December�22, 2014

�

Abbott Laboratories

(Exact name of registrant as specified in its charter)

�

�

100 Abbott Park Road

Abbott Park,�Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

�

Registrant�s telephone number, including area code: (224) 667-6100

�

Check the appropriate box below if the Form�8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

�

o����������������������������������� Written communications pursuant to Rule�425 under the Securities Act (17 CFR 230.425)

�

o����������������������������������� Soliciting material pursuant to Rule�14a-12 under the Exchange Act (17 CFR 240.14a-12)

�

o����������������������������������� Pre-commencement communications pursuant to Rule�14d-2(b)�under the Exchange Act (17 CFR 240.14d-2(b))

�

o����������������������������������� Pre-commencement communications pursuant to Rule�13e-4(c)�under the Exchange Act (17 CFR 240.13e-4(c))

�

�

�

Item 5.02������������������������������������������ Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

�

As previously reported, Abbott has Agreements Regarding Change in Control (�Agreements�) with its named executive officers, other than Miles D. White, Abbott�s Chairman of the Board and Chief Executive Officer, who is not party to an Agreement Regarding Change in Control.

�

The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December�31, 2014), the Agreement�s term shall continue through the second anniversary of the Expiration Date.

�

On December�22, 2014, Abbott notified the named executive officers who are party to the Agreements that the term of the Agreements was extended through December�31, 2016.

�

2

�

SIGNATURES

�

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

�

Dated:� December�23, 2014	ABBOTT LABORATORIES
�	�
�	�
�	By:	/s/ Thomas C. Freyman
�	�	Thomas C. Freyman
�	�	Executive Vice President, Finance and
�	�	Chief Financial Officer

�

3